Ribon Therapeutics recently presented a potent and selective small molecule inhibitor of TIPARP (PARP7), referred to as RBN-2397 that enhances IFN-I signaling and causes lung cancer regression in xenograft models (Vasbinder et al., 2020). Here, TIPARP is linked to lung carcinoma.